Ménétrier's disease

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics
| Ménétrier's disease | |
|---|---|
| Synonyms | Hyperplastic hypersecretory gastropathy |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Abdominal pain, nausea, vomiting, edema, weight loss |
| Complications | Protein-losing enteropathy, gastric cancer |
| Onset | Typically in adulthood |
| Duration | Chronic |
| Types | N/A |
| Causes | Unknown, possibly related to cytomegalovirus or Helicobacter pylori infection |
| Risks | Male gender, middle age |
| Diagnosis | Endoscopy, biopsy, imaging studies |
| Differential diagnosis | Zollinger-Ellison syndrome, gastritis, gastric lymphoma |
| Prevention | N/A |
| Treatment | Proton pump inhibitors, anticholinergics, octreotide, gastrectomy |
| Medication | N/A |
| Prognosis | Variable, risk of malignancy |
| Frequency | Rare |
| Deaths | N/A |

Ménétrier's disease, also known as giant hypertrophic gastritis, is a rare, acquired, premalignant disorder of the stomach characterized by the massive enlargement of the gastric mucosal folds. The disease is named after the French physician Pierre Ménétrier, who first described it in 1888. Ménétrier's disease primarily affects the body and fundus of the stomach, leading to protein loss, malnutrition, and, in some cases, the development of gastric cancer.
Etiology and Pathogenesis[edit]
The exact cause of Ménétrier's disease remains unclear, but it is believed to involve an overproduction of transforming growth factor alpha (TGF-Œ±), which stimulates gastric mucosal growth. This condition has been associated with Helicobacter pylori infection in some patients, suggesting a possible infectious etiology. Additionally, there is evidence to suggest a genetic predisposition to the disease.
Clinical Features[edit]
Patients with Ménétrier's disease often present with nonspecific symptoms, including nausea, vomiting, abdominal pain, and weight loss. One of the hallmark features of the disease is protein-losing enteropathy, due to the loss of protein from the enlarged gastric folds into the stomach, which can lead to edema and hypoalbuminemia.
Diagnosis[edit]
The diagnosis of Ménétrier's disease is primarily based on the clinical presentation and endoscopic findings of enlarged gastric folds. Endoscopy with biopsy is essential for confirming the diagnosis and ruling out gastric cancer. Histologically, Ménétrier's disease is characterized by foveolar hyperplasia with glandular atrophy.
Treatment[edit]
Treatment options for Ménétrier's disease are limited and primarily symptomatic. Proton pump inhibitors (PPIs) are often used to reduce gastric acid secretion and relieve symptoms. In cases associated with Helicobacter pylori infection, eradication of the bacteria may improve symptoms. For severe cases, partial gastrectomy may be considered. Recently, treatments targeting the epidermal growth factor receptor (EGFR), such as cetuximab, have shown promise in managing the disease.
Prognosis[edit]
The prognosis of Ménétrier's disease varies. While some patients may experience spontaneous remission, others may develop complications such as gastric cancer. Regular monitoring and follow-up are essential for managing the disease and detecting any malignant transformation early.
Epidemiology[edit]
Ménétrier's disease is rare, with a higher prevalence in males than in females. It is most commonly diagnosed in adults, although pediatric cases have been reported.
| Gastronomy and Gastroenterology | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
This gastronomy-related article is a stub.
|
NIH genetic and rare disease info[edit]
Ménétrier's disease is a rare disease.
| Rare and genetic diseases | ||||||
|---|---|---|---|---|---|---|
|
Rare diseases - Ménétrier's disease
|
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
